Mineralys reports positive pivotal trial results; Q1 net loss $42.2M; cash $343M

Mineralys Therapeutics, Inc.

2025-Q1 EPS reported -$0.79

Launch-HTN: 50 mg lorundrostat achieved 9.1 mmHg placebo-adjusted SBP reduction at week 6 (p<0.0001).
Advance-HTN: 50 mg cohort met primary endpoint; 7.9 mmHg placebo-adjusted SBP reduction (p=0.001).
Cash, equivalents and investments $343.0M as of March 31, 2025, vs $198.2M at Dec 31, 2024.
Net loss for Q1 2025 was $42.2M, up from $31.5M in Q1 2024; R&D expenses rose to $37.9M.
Appointed Eric Warren as Chief Commercial Officer; pre-NDA meeting with FDA expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.